Heart failure & cardiomyopathies
Comprehensive Transcriptomics Profiling of MicroRNA Reveals Plasma Circulating Biomarkers of Hypertrophic Cardiomyopathy and Dysregulated Signaling Pathways
Authors' conclusion
This study utilized comprehensive transcriptomics profiling with RNA sequencing in HCM, revealing circulating miRNA biomarkers and dysregulated pathways.
Study context
- Population
- Patients with hypertrophic cardiomyopathy (HCM) and controls with hypertensive LV hypertrophy
- Participants
- 555 patients
- Comparison
- HCM vs hypertensive LV hypertrophy
- Casesn = 392
- Controlsn = 163reference
- Outcome
- Discriminative ability (AUC) of a plasma miRNA transcriptomics-based model for HCM
Methodological detailsmulticentre, training set, prospective test set and external test set
- Multicentre
- Training set, prospective test set and external test set
Main finding
As reported in the abstract
AUC of transcriptomics-based model (derived from training set)
AUC in prospective test set
0.86
95% CI 0.79–0.93
AUC in external test set
0.94
95% CI 0.90–0.97
Observational data: associations, not effects.
Further findings
MicroRNAs (miRNAs) passing quality control
- miRNAs passed quality control filters
- 1141
Pathway analysis of dysregulated miRNAs
- Dysregulation of the Ras-MAPK pathway and inflammation-related pathways in HCM
Original publication
Comprehensive Transcriptomics Profiling of MicroRNA Reveals Plasma Circulating Biomarkers of Hypertrophic Cardiomyopathy and Dysregulated Signaling Pathways. Circ Heart Fail. Published 12 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →